10.6
Rozpuszczanie leku: wymagania i porównanie profili rozpuszczania
Kryteria akceptacji danych dotyczących profilu rozpuszczania opierają się na wartościach Q, które oznaczają procent substancji czynnej rozpuszczonej w…
Dane dotyczące profilu rozpuszczania są akceptowane na podstawie wartości Q lub procentu leku rozpuszczonego w danym czasie.
Test rozpuszczania odbywa się w trzech etapach.
Lek przechodzi etap 1 testu, jeśli wszystkie sześć jednostek dawkowania wynosi ≥ Q + 5%; W przeciwnym razie przechodzi do drugiego etapu.
Tutaj średnia z dwunastu jednostek musi wynosić ≥ Q, a żadna jednostka nie powinna być < Q - 15%; Jeśli nie, przechodzi do ostatniego etapu.
Ostatni etap wymaga, aby ≥ Q było średnio dwadzieścia cztery jednostki, przy czym nie więcej niż 2 jednostki < Q - 15% i żadna < Q - 25%.
Ponadto porównania profili rozpuszczania pomagają w opracowywaniu biorównoważnych produktów leczniczych i wykazują równoważność po zmianie formulacji.
Polega na obliczeniu współczynnika różnicowego f1 i współczynnika podobieństwa f2. Dwa profile rozpuszczania są identyczne, jeśli f1 wynosi 0, a f2 wynosi 100.
View the full transcript and gain access to JoVE Core videos
Q1: What is a Q value in drug dissolution testing?
A Q value represents the percentage of drug dissolved within a specified time period and serves as the acceptance criterion for dissolution profile data. Dissolution testing evaluates whether drug dosage units meet or exceed this Q value threshold across three sequential stages, ensuring consistent drug release and bioavailability.
Q2: How does the three-stage dissolution testing process work?
Stage 1 tests six units; all must be ≥ Q + 5% to pass. Stage 2 tests twelve units; their average must be ≥ Q with none < Q - 15%. Stage 3 tests twenty-four units; their average must meet stage 2 criteria with no more than 2 units < Q - 15% and none < Q - 25%. This progressive approach ensures rigorous quality assessment.
Q3: What happens if a drug fails stage 1 dissolution testing?
If any of the six dosage units in stage 1 fall below Q + 5%, the drug proceeds to stage 2 testing, which involves a larger sample of twelve units. This tiered system allows drugs that don't meet the initial strict criteria a second opportunity to demonstrate acceptable dissolution performance.
Q4: What are the difference factor and similarity factor in dissolution profiles?
The difference factor (f1) and similarity factor (f2) quantify differences between two dissolution profiles. Two profiles are identical when f1 equals 0 and f2 equals 100. These factors help demonstrate bioequivalence and assess whether formulation changes maintain equivalent drug release, supporting clinically relevant drug product specifications methods establishment.
Q5: Why are dissolution profile comparisons important in drug development?
Dissolution profile comparisons help develop bioequivalent drug products and demonstrate equivalence after formulation changes. By comparing f1 and f2 values between test and reference products, manufacturers ensure that modifications maintain consistent drug performance and therapeutic effectiveness throughout the product lifecycle.
Q6: What conditions must be met when comparing dissolution profiles between products?
Profile comparisons require a minimum of three dissolution time points measured on twelve drug products for both test and reference cases. At most one mean value exceeding 85% dissolved is allowable per product, and standard deviation of any product should not exceed 10% from the second to final time point.
Q7: How does dissolution testing support bioequivalent drug product development?
Dissolution testing establishes baseline drug release profiles and enables comparison between formulations using f1 and f2 factors. This in vitro drug release testing overview development and validation ensures that generic or reformulated products release drug at rates equivalent to reference products, confirming therapeutic bioequivalence.